CORRECTION OF RESISTANT ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONICKIDNEYDISEASE STAGE I–III

Aim. The aim was to investigate the use of the I1–imidazoline receptor agonist moxonidine as an ‘add–on’ agent and determine its effect on heart rate variability in patients with CKD st. I–III and resistant hypertension. Methods. We investigated the safety and efficacy of moxonidine (200–600 mg)...

Full description

Bibliographic Details
Main Author: O. M. Loboda
Format: Article
Language:English
Published: State Institution «Institute of Nephrology NAMS of Ukraine" 2014-08-01
Series:Український Журнал Нефрології та Діалізу
Subjects:
Online Access:https://ukrjnd.com.ua/index.php/journal/article/view/36